Tuesday, October 4, 2022


Biotechnology News Magazine

Jesse Hall MD, Appointed CMO of AltruBio

“Jesse Hall MD depth of experience leading clinical development in immunology will help us to advance our novel therapeutic candidates in this disease area and to bring the therapeutics to patients,” said Judy Chou, Chief Executive Officer of AltruBio. “The addition of Dr. Hall is a milestone to further strengthen our leadership team and to complete the corporate turnaround we began almost 18 months ago.”

Dr. Hall added, “I’m thrilled to join AltruBio and contribute to the growth of the company in developing more targeted treatments for immunological diseases. As a physician, I see the need for developing new treatments with fewer side effects for patients with these diseases. My deep passion for drug development and for assessing the best clinical outcomes for patients aligns with the AltruBio’s vision, and I am eager to help strengthen the clinical strategy and guide its drugs candidates towards the next stage of development.”

Prior to joining AltruBio, Dr. Hall served as Executive Vice President and chief medical officer at Sublimity Therapeutics. He was responsible for leading the company’s clinical development efforts across multiple disease indications and provided guidance on the life-cycle management of the Sublimity portfolio and led clinical due diligence on potential in-licensing and collaboration opportunities. Prior to joining Sublimity, Dr. Hall served as an executive medical director of Ardea Biosciences, medical director at Amgen, and associate medical director at Abbott Laboratories, respectively.

Dr. Hall earned his M.D. from University of Oklahoma College of Medicine and a B.A. in Ocean Studies with a minor in Economics from University of San Diego.

Biotechnology News Magazine
Biotechnology News Magazine reports the latest biotech, pharma, FDA updates, biotechnology clinical trials, biotechnology mergers, biotechnology acquisitions, biotechnology funding, articles of interest and other important news.